 HONG KONG--BUSINESS WIRE--Regencell Bioscience Holdings Limited NASDAQ:RGC Regencell or the Company, an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine TCM for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder ADHD and Autism Spectrum Disorder ASD, today announced that the underwriter of its initial public offering the Offering had 